Samira M Sadowski
Overview
Explore the profile of Samira M Sadowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huber A, Demarchi M, Verissimo T, Fernandez M, Dufey A, Berchtold L, et al.
Eur J Endocrinol
. 2025 Mar;
PMID: 40067841
Introduction: Primary hyperparathyroidism (PHPT) often causes hypercalcemia and complications requiring parathyroidectomy (PTX). Anemia affects 15-50% of PHPT patients, but its mechanisms remain unclear. While parathyroid hormone (PTH) and fibroblast growth...
2.
Ear P, Marinoni I, Dayton T, Guenter R, Quelle D, Battistella A, et al.
Endocr Oncol
. 2025 Jan;
4(1):e240055.
PMID: 39822778
Current models for the study of neuroendocrine tumours (NETs) are severely limited. While (e.g. cell lines), (e.g. organoids) and (e.g. mice) models all exist, each has limitations. To address these...
3.
Ghabra S, Ramamoorthy B, Andrews S, Sadowski S
Surg Clin North Am
. 2024 Jun;
104(4):891-908.
PMID: 38944507
Pancreatic neuroendocrine tumors (PNETs) arise from neuroendocrine cells and are a rare class of heterogenous tumors with increasing incidence. The diagnosis, staging, treatment, and prognosis of PNETs depend heavily on...
4.
Gustafson A, Sadowski S
Ann Surg Oncol
. 2024 Jun;
31(9):5487-5488.
PMID: 38839670
No abstract available.
5.
Forsythe S, Pu T, Andrews S, Madigan J, Sadowski S
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568572
Pancreatic neuroendocrine neoplasms (pNENs) are a heterogeneous group of tumors derived from multiple neuroendocrine origin cell subtypes. Incidence rates for pNENs have steadily risen over the last decade, and outcomes...
6.
Sharma R, Earla B, Baidoo K, Zeiger M, Madigan J, Escorcia F, et al.
Mol Cancer Ther
. 2023 Jul;
22(9):1052-1062.
PMID: 37487000
Pancreatic neuroendocrine tumors (PNET) express high levels of somatostatin receptor type 2 (SSTR2), a unique target for both tumor imaging and therapy. This surface expression is lost in metastatic high-grade...
7.
Schmidlin M, Sadowski S, Siebenhuner A, Wild D, Christ E, Refardt J
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190198
Typical (TC) and atypical carcinoids (AC) are the most common neuroendocrine tumors (NETs) of the lung. Because these tumors are rare, their management varies widely among Swiss centers. Our aim...
8.
Jha S, Welch J, Tora R, Lack J, Warner A, Del Rivero J, et al.
J Clin Endocrinol Metab
. 2023 Mar;
108(10):2686-2698.
PMID: 36935552
Context: Parathyroid cancer (PC) is a rare endocrine neoplasm with high mortality. While surgery is the treatment for patients with the disease, recurrence rates are high, and patients usually succumb...
9.
King A, Gutsche N, Raju N, Fayn S, Baidoo K, Bell M, et al.
J Nucl Med
. 2022 Nov;
64(4):549-554.
PMID: 36396453
Neuroendocrine tumors (NETs) express somatostatin receptors (SSTRs) 2 and 5. Modified variants of somatostatin, the cognate ligand for SSTR2 and SSTR5, are used in treatment for metastatic and locoregional disease....
10.
Dominguez D, Chatani P, Murphy R, Copeland A, Chang R, Sadowski S, et al.
Ann Surg Oncol
. 2021 May;
28(12):7487-7495.
PMID: 33939050
Background: Adrenal venous sampling (AVS) is recommended before adrenalectomy for patients with primary aldosteronism (PA) over 35 years old. The literature examining contralateral suppression (CoS) on AVS in predicting surgical...